An organ-on-a-chip is a device that combines micro-manufacturing and tissue engineering to replicate the critical physiological environment and functions of the human organs. Therefore, it can be used to predict drug responses and environmental effects on organs. Microfluidic technology can control micro-scale reagents with high precision. Hence, microfluidics have been widely applied in organ-on-chip systems to mimic specific organ or multiple organs in vivo. These models integrated with various sensors show great potential in simulating the human environment. In this review, we mainly introduce the typical structures and recent research achievements of several organ-on-a-chip platforms. We also discuss innovations in models applied to the fields of pharmacokinetics/pharmacodynamics, nano-medicine, continuous dynamic monitoring in disease modeling, and their further applications in other fields.
To enhance the surface biocompatibility of silicon-based materials used in micro-biomedical devices, nitrogen plasma immersion ion implantation (PIII) was performed on single-crystal silicon wafers. The platelet activation behavior on the N-PIII silicon was investigated in vitro, and the results indicate that the nitrogen plasma-treated surface exhibits less platelets activation than low temperature isotropic pyrolytic carbon (LTIC) that is a common material used in blood-contacting implants such as artificial heart valves. Our results also indicate that Si–N bonds enhance the surface hydrophilicity and combined with good critical surface tension, activation of platelets is mitigated. The mechanism of the platelet activation reactions is discussed from the perspective of the surface energy.
4 March 2025 in IEEE Transactions on Instrumentation and Measurement
Hybridoma cell screening is crucial for the production of monoclonal antibodies; however, traditional screening methods are often time-consuming and reliant on antigen-antibody labeling. This study introduces a label-free, single-cell, multi-frequency impedance detection system that innovatively utilizes impedance spectra as a novel physical parameter to differentiate between various hybridoma and myeloma cell types. The sensing device integrates dual-funnel structures with coplanar electrodes, which are respectively utilized for cell capture and impedance measurement. By optimizing the excitation voltage and flow rate, the system effectively reduces measurement errors. The sensing device was validated using polystyrene microbeads of different diameters, yielding coefficients of variation (CV) of 0.0241% and 0.0132%, indicating high measurement stability and repeatability. The system was further validated with two types of hybridoma cells (E5, CD2) and myeloma cells (SP20), and impedance data were analyzed using orthogonal partial least squares discriminant analysis (OPLS-DA) via SIMCA 14.5 software, achieving a model prediction accuracy of 0.974. The results demonstrate that the system can stably and accurately measure cell impedance spectra, and that impedance spectra, as a label-free parameter, can effectively distinguish between different types of hybridoma and myeloma cells, showing great potential for hybridoma cell sorting.
Cancer cell spheroids have been shown to mimic in vivo tumour microenvironment and are therefore suitable for in vitro drug screening. Microfluidic technology can provide conveniences for spheroid assays such as high‐throughput, simplifying manual operation and saving reagent. Here, we propose a concentration gradient generator based on microfluidic technology for cell spheroid culture and assay. The chip consists of upper microchannels and lower microwells. After partitioning HepG2 suspension into the microwells with concave and non‐adhesive bottoms, spheroids can spontaneously form. By controlling the fluid replacement and flow in microchannels, the doxorubicin solution is diluted automatically into a series of concentration gradients, which spanning more than one order of magnitude. And then the effect of doxorubicin on spheroids is measured in situ by fluorescent staining. This chip provides a very promising approach to achieve the high‐throughput and standardized anti‐cancer drug screening in future.